-
2024-517300-10-01
5
2020-12-17
Resectable diffuse type gastric and gastroesophageal junction Typ II/I
-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-513950-32-00
4
2020-12-15
Intermediate stage hepatocellular carcinoma (HCC)
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-512528-13-00
1
2020-05-27
Multiple System Atrophy
-
2024-514494-21-00
4
2020-05-13
autoimmune encephalitis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-517236-22-00
5
2017-09-20
Intradural saccular unruptured aneurysm
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-521624-30-00
4
2026-01-08
Atopic dermatitis
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2023-503539-16-00
5
2025-11-11
Non-small Cell Lung Cancer (NSCLC)
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2024-519417-57-00
5
2025-06-25
Thyroid eye disease
-
2024-514133-38-00
5
2025-03-19
Ocular Myasthenia Gravis
-
2024-514973-23-00
5
2025-02-25
Thyroid eye disease
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2023-508055-40-00
6
2025-02-18
Obesity
-
2023-508276-11-00
5
2025-01-17
Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal J
-
2024-511881-35-00
5
2024-12-17
Prurigo Nodularis
-
2023-504040-34-01
5
2024-11-12
Crohn’s Disease
-
2024-511796-15-00
5
2024-10-16
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
-
2023-505739-12-01
5
2024-09-30
Chronic Inducible Urticaria (CINDU)